Showing results (1541-1550 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|April 13, 2023
Brigatinib pharmacokinetics in patients with chronic hepatic impairmentMichael J Hanley, David Kerstein, Meera Tugnait, et al.
Investigational New Drugs|January 1, 1986
Quantitation of differential sensitivity of normal marrow myeloid progenitor cells to anthracene derivativesD Bron, P Dodion, M Rozencweig, et al.
Investigational New Drugs|January 1, 1986
Biochemical and biological activity of the anthracycline analog, 4-demethyl-6-O-methyl-doxorubicinF Zunino, B Barbieri, O Bellini, et al.
Investigational New Drugs|January 1, 1986
Phase II trial of acivicin in patients with advanced epithelial ovarian carcinoma. A Gynecologic Oncology Group StudyW P McGuire, J A Blessing, P J DiSaia, et al.
Investigational New Drugs|April 2, 2023
Development of a MET-targeted single-chain antibody fragment as an anti-oncogene targeted therapy for breast cancerRana Vafaei, Zohreh Khaki, Malihe Salehi, et al.
Investigational New Drugs|April 2, 2023
Complete Response to tenalisib and romidepsin with long-term maintenance using tenalisib monotherapy in a patient with relapsed and refractory sézary syndromeChristopher N Nguyen, Swaminathan P Iyer, Madeleine Duvic, et al.
Investigational New Drugs|April 9, 2021
Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancerHiroto Inoue, Akiko Todaka, Kentaro Yamazaki, et al.
Investigational New Drugs|June 20, 2008
In vitro cytotoxic activity of tri-n-butyltin(IV)lupinylsulfide hydrogen fumarate (IST-FS 35) and preliminary antitumor activity in vivoAngela Alama, Maurizio Viale, Michele Cilli, et al.
Investigational New Drugs|June 10, 2006
Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and Bleomycin-CCNU in patients with advanced cancer of the anal canal: An eastern cooperative oncology group study E7282Minaxi Jhawer, Sridhar Mani, Myrto Lefkopoulou, et al.
Investigational New Drugs|February 1, 1991
A phase II study of taxol in patients with malignant melanomaA I Einzig, H Hochster, P H Wiernik, et al.
Pageof 372